Navigation Links
Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
Date:12/1/2011

inical study of LBH589 in combination with INC424 in JAK2V617F-driven disease (ASH abstract #798; December 12, 4:30 – 6:00PM).

About everolimus
In the US, Afinitor® (everolimus) tablets is approved for the treatment of progressive neuroendocrine tumors of pancreatic origin (pNET) in patients with unresectable, locally advanced or metastatic disease and for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. The US Food and Drug Administration (FDA) determined that the safety and effectiveness of Afinitor in the treatment of patients with carcinoid tumors have not been established.

Afinitor is also approved in the US to treat patients with SEGA associated with TS who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of everolimus is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been shown.

In the US, everolimus is available from Novartis in different dosage strengths and for different uses in non-oncology patient populations under the trade name Zortress®. Everolimus is exclusively licensed to Abbott and sublicensed to Boston Scientific for use in drug-eluting stents.

Not all indications are available in every country. Access to everolimus outside of the approved indications has been carefully controlled and monitored in clinical trials designed to better understand the potential benefits and risks of the compound. As an investigational compound, the safety and efficacy profile of everolimus has not yet been established outside the approved indications. Because of the uncertainty of clinical trials, there is no guarantee that everolimus will become commercially available for additional indications anywhere else in the world.

'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
2. Genentech and Novartis Remain Image Leaders in Oncology and Hematology
3. FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD
4. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
5. With the Recent Launch of Novartiss Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
6. VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
7. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
8. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
9. Novartis Class Awarded $250 Million in Punitive Damages
10. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
11. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ... today reported results of its Oral Amphotericin B ... reservoirs.  The study, conducted by ImmuneCarta®, the immune ... vitro effectiveness of Oral Amp B in ... in individuals despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... FREDERICK, Md. , Aug. 18, 2014 ... the maker of advanced consumer medical devices ... Kotak was interviewed by CEOLIVE.TV as ... The entire interview is available at ... interview Dr. Kotak explains to investors the ...
(Date:8/18/2014)... According to the new ... (Municipal Wastewater Treatment and Industrial Wastewater Treatment), By ... By Configuration (Internal/Submerged and External/Sidestream), and By Region-Trends ... market for membrane bioreactor systems is projected to ... CAGR of 15.28% between 2014 and 2019. ...
(Date:8/16/2014)... NY (PRWEB) August 16, 2014 ... industry provide guidance and advisory services to ... and technical issues. Industry services are highly diverse ... Therefore, industry services range from geological and geophysical ... plans. “Consequently, over the past five years, the ...
Breaking Biology Technology:iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 2Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 3
... outstanding share of common stock of Bruker AXS will be ... common stock of Bruker Daltonics or, at the election of ... value, payable 75% in Bruker Daltonics common stock and 25% ... are not being changed in the merger. , ,The combined ...
... labs, technology, research, communication and planning , ,WASHINGTON ... the Department of Health and Human Services has made ... of states, territories and metro areas to respond to ... to receive $25 million, of which almost $16 Million ...
... and Human Services announced last week the development of ... Emerging Infectious Diseases Research. The University of Wisconsin-Madison is ... Midwestern center as part of a $350 million national ... Chicago and Northwestern University will receive $35 million in ...
Cached Biology Technology:Bruker Daltonics and Bruker AXS Announce Merger Agreement 2Wisconsin to Receive $25 Million for Bioterrorism 2UW-Madison Gets Federal Biodefense Funds 2
(Date:8/18/2014)... 2014 Researchers at UT Southwestern Medical Center have found ... a type of molecule known as long non-coding RNA. , ... "rhythms" of many bodily functions, from waking and sleeping to ... 24-hour cycle that is influenced by external cues such as ... RNAs are abundant in many organisms, what they do in ...
(Date:8/18/2014)... indicates older species of coral have more of what ... climate, according to biologists from the University of Texas ... Mayagez., The researchers examined 140 samples of 14 species ... open-access journal PLOS ONE on Aug. 18. ... the UT Arlington Department of Biology, is lead author ...
(Date:8/18/2014)... kill its ant hosts outside their nest to reproduce ... in the vicinity of the colony, ensuring a constant ... Penn State and colleagues at Brazil,s Federal University of ... Previous research shows that Ophiocordyceps camponoti-rufipedis , known ... carpenter ant workers -- Camponotus rufipes -- ...
Breaking Biology News(10 mins):Researchers obtain key insights into how the internal body clock is tuned 2Researchers obtain key insights into how the internal body clock is tuned 3Older coral species more hardy, UT Arlington biologists say 2Zombie ant fungi manipulate hosts to die on the 'doorstep' of the colony 2Zombie ant fungi manipulate hosts to die on the 'doorstep' of the colony 3
... it possible to solve climate change, reduce poverty and save ... dream, but this is exactly the issue that is being ... Bali 3-14 December 2007. The key is to include reduced ... so that developing countries can be compensated for saving their ...
... Topics include: onset of plate tectonics on Earth; Arctic ... the end-Permian mass extinction; Olduvai Basin lake cycles and ... the break-up of Rodinia; relationship between earthquakes and melting ... and cause of the end of the PETM. The ...
... frogs can be crowded out by immigrant or imported ... The scientists investigated water frog populations in France and ... ridibunda), which normally occurs only in Eastern Europe, has ... hybrid frog (Rana grafi) and the Iberian water frog ...
Cached Biology News:Having the climate cake and eating it, too 2December GEOLOGY and GSA TODAY media highlights 2December GEOLOGY and GSA TODAY media highlights 3December GEOLOGY and GSA TODAY media highlights 4December GEOLOGY and GSA TODAY media highlights 5December GEOLOGY and GSA TODAY media highlights 6December GEOLOGY and GSA TODAY media highlights 7December GEOLOGY and GSA TODAY media highlights 8December GEOLOGY and GSA TODAY media highlights 9December GEOLOGY and GSA TODAY media highlights 10Indigenous water frogs under threat 2
...
... measures NOS activity by monitoring the conversion ... is simple, sensitive, and specific for NOS ... crude and purified enzyme preparations. The kit ... total reactions. Radiolabeled arginine and NADPH are ...
Human TSLP MAb (Clone 258136)...
Human Complement Component C5a MAb (Clone 295003)...
Biology Products: